causal
Biotech Rose as Small-Molecule Pharma Declined
Two curves overlapped in pharma history: the exhaustion of low-hanging fruit in small-molecule chemistry and the growth of biotechnology built on recombinant DNA, which allowed bacteria to produce arbitrary proteins such as humanized insulin and monoclonal antibodies.
causalpending
Speaker
AlexEvidence Quote
“the growth in what we can do with biotechnology tools like recombinant DNA and more recently, CRISPR”
Source
Alex Telford - Unlocking Innovation in Pharma - [Invest Like the Best, EP.360]— Invest Like the BestCreated: 11/14/2026, 6:42:06 AM
Your notes
Loading notes...